Somewhat Favorable News Coverage Somewhat Unlikely to Affect Progenics Pharmaceuticals (NASDAQ:PGNX) Stock Price

Media coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.8544515935052 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Progenics Pharmaceuticals (NASDAQ PGNX) traded down $0.15 during trading on Tuesday, hitting $5.45. The stock had a trading volume of 819,600 shares, compared to its average volume of 1,108,675. Progenics Pharmaceuticals has a 1-year low of $4.60 and a 1-year high of $11.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The company had revenue of $2.70 million during the quarter, compared to the consensus estimate of $3.58 million. During the same quarter in the prior year, the firm posted $0.52 earnings per share. Progenics Pharmaceuticals’s revenue for the quarter was down 95.0% on a year-over-year basis. analysts predict that Progenics Pharmaceuticals will post -0.92 EPS for the current year.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. ValuEngine cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Cantor Fitzgerald set a $15.00 price objective on Progenics Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Aegis reiterated a “buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Tuesday, August 22nd. Finally, Needham & Company LLC reiterated a “strong-buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $13.20.

COPYRIGHT VIOLATION WARNING: This piece was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2017/11/14/progenics-pharmaceuticals-pgnx-earning-somewhat-favorable-press-coverage-analysis-finds.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Insider Buying and Selling by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply